A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Phase 2CompletedNCT02094365

Alios Biopharma Inc.62 enrolled

Overview

This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Respiratory Syncytial Virus Infections

Interventions

ALS-008176DRUG

vehicleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 to 45 years, inclusive. * In good health with no history of major medical conditions * A total body weight ≥ 50 kg and a body mass index (BMI) of \> 18kg/m2. Exclusion Criteria: * Acute or chronic medical illness * Positive for Human Immunodeficiency Virus, Hepatitis B or C * Nose or nasopharynx abnormalities * Abnormal lung function

Locations (1)

Retroscreen Virology Ltd

London, United Kingdom

Outcomes

Primary Outcomes

Change in viral load measurements.

Time frame: Baseline to day 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.